Circulating cell-free tumor DNA (ctDNA) can serve as a real-time biomarker of tumor burden
and provide unique insights into the evolving molecular landscape of cancers under the …

Tissue-based biopsy is the present main tool to explore the molecular landscape of cancer,
but it also has many limits to be frequently executed, being too invasive with the risk of side …

ECOG performance status (PS) is a pivotal prognostic factor in a wide number of solid
tumors. We performed a meta-analysis to assess the role of ECOG PS in terms of survival in …

Abstract Purpose: Neoadjuvant anti–PD-1 therapy has shown promise for resectable non–
small cell lung cancer (NSCLC). We reported the first phase I/II trial of neoadjuvant …

Background We evaluated whether tissue tumor mutational burden (tTMB) and STK11,
KEAP1, and KRAS mutations have clinical utility as biomarkers for pembrolizumab …

Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in
both research and clinical settings. ctDNA can be used to identify actionable mutations to …

Simple Summary The tumor mutational burden (TMB) can be defined as the number of
somatic mutations per megabase of the sequenced genome. It correlates with tumor …

Lung cancer has the highest mortality rate among all cancer types, resulting in over 1.8
million deaths annually. Immunotherapy utilizing immune checkpoint inhibitors (ICIs) has …

Plasma circulating tumor DNA (ctDNA) represents short fragments of tumor-derived DNA
released into the bloodstream primarily from cancer cells undergoing apoptosis. In …

Background Cancer immunotherapy shows unique efficacy kinetics that differs from
conventional treatment. These characteristics may lead to the prolongation of trial duration …